Samantha Pozzi

ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

Massimo Federico, Stefano Luminari, Emilio Iannitto et al. · Journal of Clinical Oncology · 2009 · 272 citations · Full text

Medicine, Oncology, Pharmacology +12

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

Siddhartha Mukherjee, Noopur Raje, Jesse Schoonmaker et al. · Journal of Clinical Investigation · 2008 · 240 citations · Full text

Medicine, Biomedical Engineering, Bone Metabolism +16

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

Sonia Vallet, Siddhartha Mukherjee, Nileshwari Vaghela et al. · Proceedings of the National Academy of Sciences · 2010 · 235 citations · Full text

Medicine, Cell Biology, Oncology +17

The Monoclonal Antibody nBT062 Conjugated to Cytotoxic Maytansinoids Has Selective Cytotoxicity Against CD138-Positive Multiple Myeloma Cells <i>In vitro</i> and <i>In vivo</i>

Hiroshi Ikeda, Teru Hideshima, Mariateresa Fulciniti et al. · Clinical Cancer Research · 2009 · 204 citations · Full text

Medicine, Oncology, Pharmacology +14

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells

Tanyel Kiziltepe, Teru Hideshima, Laurence Catley et al. · Molecular Cancer Therapeutics · 2007 · 179 citations · Full text

Medicine, Oncology, Pharmacology +17